Zila Nutraceuticals
This article was originally published in The Tan Sheet
Executive Summary
Ronald Fugate named VP and general manager of Zila Nutraceuticals, Phoenix-based firm announces Sept. 18. Fugate brings experience from J&J, Kellogg Functional Foods Division to post; he most recently served as senior director-marketing at Bristol-Myers Squibb's Consumer Medicines division, where he led Pravachol Rx-to-OTC switch attempt (1"The Tan Sheet" July 24, 2000, p.12). In his new role, Fugate will look to introduce Zila's Ester-C vitamin C ingredient into new vitamin products. In a Sept. 18 conference call, Zila President & CEO Doug Burkett, PhD, said the firm expects to see 25% top line growth for Ester-C in 2002; ingredient recorded roughly $20 mil. in sales in 2001, firm says...
You may also be interested in...
OTC Statin Physician Follow-Up Label Comprehension Not Shown - FDA
Merck and Bristol Myers-Squibb should design label comprehension studies that do not assume consumers would understand how to use Mevacor and Pravachol in an OTC setting, FDA's Karen Lechter, PhD, advised during joint meetings of the Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees July 13-14.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.